Toni Choueiri, MD

Excellent overview by @AlbigesL on HIF-2α inhibition in RCC at #ESMO26! • LITESPARK-011: belzutifan + lenvatinib improved ORR/PFS, but not OS • Optimal combinations & sequencing remain unclear • Casdatifan: promising activity (ORR 35%) • Serum EPO: potential response biomarker @myESMO @oncoalert

Thought-provoking presentation by @DrDanielHeng ! LITESPARK-011: better baseline quality of life was associated with longer PFS and OS in an exploratory analysis of 741 patients. Another reason to keep patient-reported outcomes central! #ESMO26 @oncoalert @myESMO https://t.co/G5aW8OQQkB

Post-IO RCC update by @DrDanielHeng in LITESPARK-011 Ph.III: Bel/Len vs Cabo maintained PFS benefit (14.8 vs 10.8 mo; HR 0.74). ORR 53% vs 40%; DOR 22 vs 12 mo. OS favored Bel/Len (33.7 vs 28.6 mo; HR 0.85) but missed significance boundary. #ESMO26 #RCC @myESMO @OncoAlert https://t.co/WMYWwaAPYD

Esciting presentation by @Albert0Briganti ! PROTEUS substudy: adding perioperative apalutamide + ADT to surgery improved EFS in high-risk localized/locally advanced PCa (HR 0.38). Important randomized evidence for intensification! @myESMO #ESMO26 @oncoalert https://t.co/QpfB0YpW6j

Our very own Prof. Mary-Ellen Taplin from @DanaFarber_GU opens up the plenary session at #ASCO26 with practice-changing results from the phase 3 PROTEUS trial. Perioperative apalutamide + ADT significantly improved pathologic response rates (8.9% vs 1.0%) and metastasis-free survival (HR 0.80) in HR LPC/ LAPC. #ASCO #ProstateCancer @OncoAlert @ASCO @DanaFarber

@DanaFarber_GU ’s very own Prof. Mary-Ellen Taplin opens up the plenary session at #ASCO26 with practice-changing results from the phase 3 PROTEUS trial. Perioperative apalutamide + ADT significantly improved pathologic response rates (8.9% vs 1.0%) and metastasis-free survival (HR 0.80) in HR LPC/ LAPC. #ASCO #ProstateCancer @OncoAlert @ASCO @DanaFarber

JUST IN: @FDA approved talazoparib plus enzalutamide for adults with HRR gene-mutated metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer, with mutations detected by an FDA-authorized test. Approval based on TALAPRO-3 Trial led by @neerajaiims, now @DanaFarber_GU 52% reduction in the hazard of radiographic progression or death (HR 0.48; 95% CI 0.36–0.65).

JUST In: TALAPRO-3 published in @NEJM Adding #talazoparib to enzalutamide/ADT =>3-year rPFS: 77% vs 56% in HRR-deficient metastatic prostate cancer ! Looking forward to full presentation by @neerajaiims who keeps changing SOC, one trial at a time. @ASCO #ASCO26 @OncoAlert https://t.co/nXiPk4DIXg

@neerajaiims presents impressive phase III TALAPRO-3 data with concomitant publication in @NEJM: talazoparib + enzalutamide significantly prolonged rPFS in HRR-altered mCSPC (HR 0.48), with particularly striking benefit in BRCA-mutated disease and consistent activity beyond BRCA alterations. #ASCO26 #ProstateCancer @OncoAlert @ASCO @OncBrothers

🚨 Results from #LITESPARK022 (#LS022) are out in @NEJM! 1/This phase III trial evaluated whether adding the HIF-2α inhibitor Belzutifan (BEL) to adjuvant pembrolizumab (PEMBRO) could improve outcomes for patients with resected clear-cell RCC at increased risk for recurrence. https://t.co/1BLAercj3p @oncoalert @asco @myESMO

8/In conclusion, #LITESPARK022 demonstrated that the addition of BEL to adjuvant pembrolizumab significantly improved DFS. This regimen has now led to @US_FDA approval of pembrolizumab + belzutifan June 12, 2026 for patients with ccRCC at increased risk of recurrence after surgery. https://t.co/79LKcR4hcz A new chapter in adjuvant RCC therapy! We have the first COMBINATION in adjuvant RCC

3/ #LITESPARK022 enrolled patients with surgically resected ccRCC at increased risk of recurrence, including those with M1 NED (no evidence of disease). A total of 1841 patients were randomized 1:1 to pembrolizumab + belzutifan (n=921) or pembrolizumab + placebo (n=920). Median follow-up was 28.4 months. The primary endpoint was DFS, with OS and safety as key secondary endpoints Baseline characteristics were balanced between both arms

JUST IN: DeLLphi-305: Small Cell Lung Cancer Extensive-Stage Phase III (n=563): Tarlatamab + Durvalumab vs Durvalumab as 1L maintenance after chemo-IO, to be presented by our own @sands_jacob from @DanaFarber • Median OS: 21.1 vs 12.7 months (HR 0.42) • Median PFS: 7.4 vs 1.9 months (HR 0.34) • ORR: 26.4% vs 4.1% Grade ≥3 AEs: 46.8% vs 40.6%; CRS 49.6% (most low grade). Probably new standard of care in ES-SCLC. @OncoAlert @DanaFarberNews #ESMO26

Outstanding presentation by our very own @DanaFarber @sands_jacob ! DeLLphi-305: tarlatamab + durvalumab vs durvalumab as 1L maintenance in ES-SCLC improved median OS to 21.1 vs 12.7 months (HR 0.42). A major advance for patients with SCLC! #ESMO26 @oncoalert @myESMO https://t.co/UxKz3Qgjp7

JUST IN: DeLLphi-305 study met its primary endpoint of overall survival combining tarlatamab (DLL3 BiTE) with PDL1 inhibitor Durvalumab as maintenance after 1L chemotherapy for extensive-stage small cell lung cancer ! Also RR/PFS significant Trial led by @DanaFarber @sands_jacob ! Via @PRNews https://t.co/mbVxkzeAmz

Excellent presentation by @tompowles1! VOLGA: perioperative durvalumab + 3 cycles of neoadjuvant EV improved EFS (HR 0.51) and OS (HR 0.58) vs cystectomy ± adjuvant therapy in cisplatin-ineligible/declining MIBC. ADCs moving earlier! #ESMO26 @oncoalert @myESMO https://t.co/ex3NdpxzoI

Priority review by the @FDA for neoadjuvant EV+Durvalumab based on #VOLGA study which is not yet presented!, but soon at #ESMO26 Interesting—and somewhat unusual—to see a Priority Review announcement with a PDUFA action date already in Q4 2026. The perioperative bladder cancer space is moving very fast. #bladdercancer #GUonc @OncoAlert @DanaFarber_GU @myESMO @AstraZeneca @AstraZenecaUS @OncoBellmunt @tompowles1 https://t.co/ITWEX1lQMo

JUST IN: VOLGA Phase III is (+)=>Neoadjuvant Durva+EV and adjuvant Durva alone showed EFS & OS benefit. The shorter period of EV is a very attractive option! @DanaFarber_GU @OncoAlert @OncBrothers @AstraZeneca @tompowles1 @AUC3_Official https://t.co/2fST9O16Qb

Elegant presentation by @Uro_Oncologist reporting HRQoL from #Keynote-B15. Perioperative EV-P was not associated with clinically meaningful detriment in general HRQoL or cystectomy-specific HRQoL ! #ESMO26 #Day2 @myESMO @OncoAlert https://t.co/eSoiNht3Jw

ctDNA insights from KEYNOTE-B15 by #DrJonathanChatzkel: perioperative EV + Pembro vs Gem/Cis in cis-eligible MIBC. ctDNA clearance 82.1% vs 66.7%. Post-surgery ctDNA+ 4.8% vs 13.5%. EFS benefit with EV/Pembro across baseline ctDNA strata, exploratory ctDNA+ HR 0.54. #ESMO26 #BladderCancer @myESMO @OncoAlert

Major practice changing peri-op readout by @MattGalsky, KEYNOTE-B15/EV-304: EV+pembro peri-op vs neoadj GC + surgery → trial met endpoints with significant EFS (HR 0.53, p<0.001) + OS (0.65, p =0.0029) + pCR improvement (23.4% sig difference) @OncoAlert @OncBrothers #GU26 #BladderCancer

#MariaDeSantis reporting outcomes of pts with papillary only tumors from #POTOMAC #NMIBC Addition of Durva to BCG (I+M): • Fewer early high-risk disease recurrences • Fewer BCG unresponsive recurrences • Fewer cystectomies #ESMO26 #Day2 @myESMO @OncoAlert https://t.co/ora8w2QGf8

POTOMAC 5-year OS update presented by Dr Maria De Santis: Durvalumab + BCG (I+M) continues to show no detriment to OS vs BCG alone in BCG-naive high-risk NMIBC (5-yr OS 87.6% vs 86.3%), with no major impact on quality of life. #ASCO26 #BladderCancer @OncoAlert @ASCO @OncBrothers https://t.co/rJezlmYq9w

JUST IN: @US_FDA approves Durvalumab + BCG in high-risk non-muscle invasive bladder cancer (T1 tumor, grade 3/high-grade tumor, carcinoma in situ, or multiple, recurrent, and large tumors) based on phase III POTOMAC trial (NCT03528694), showing DFS (HR 0.68); via @UrologyTimes https://t.co/ziJZbT4wvU